The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2019 | CANFOUR: targeting IL1RAP for NSCLC or pancreatic cancer

Name: CANFOUR: targeting IL1RAP for NSCLC or pancreatic cancer
Uploaded: 2019-06-02T00:00:00Z
Duration: 3 min 34 s
Description: Ahmad Awada, MD, PhD, of the Jules Bordet Cancer Institute, Brussels, Belgium, discusses the CANFOUR trial (NCT03267316) investigating nadunolimab, a monoclonal antibody targeting IL1RAP for patients with non-small cell lung cancer (NSCLC) or pancreatic cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Ahmad Awada • 2 Jun 2019

ASCO 2019

Lung Cancer Non-Small Cell Lung Cancer Pancreatic Cancer

CANFOUR

Ahmad Awada, MD, PhD, of the Jules Bordet Cancer Institute, Brussels, Belgium, discusses the CANFOUR trial (NCT03267316) investigating nadunolimab, a monoclonal antibody targeting IL1RAP for patients with non-small cell lung cancer (NSCLC) or pancreatic cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.